PCSK9 and atherosclerosis: For monoclonal antibodies targeting cardiovascular indications (e.g., PCSK9 inhibitors, anti-IL-1β for atherosclerosis), PBPK/QSP modeling leveraging human tissue distribution data represents a promising direction that could reduce or complement, rather than eliminate, long-term primate pharmacokinetic studies [11,12].